Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

The recipient, a liver cirrhosis patient who has been recuperating well since the Jan 20 transplant, went back home on Monday in good health. When the doctors embarked on the transplant ...

Innovative therapies and surgical techniques have the potential to transform liver cancer care. People with cirrhosis—a ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into treatment, the patient reports ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

(RTTNews) - Can-Fite BioPharma Ltd. (CANF), announced on Tuesday that a patient experienced the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson ...

Discover a potential breakthrough in treating severe liver scarring with a safe and effective therapy, as revealed by a recent Cleveland Clinic-led study.

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients ... 3 SYNCHRONY Real-World study ...